Insider · SEC Form 4 filer
Robert Williamson
Past buys: 3 of 3 beat
Companies
Where they file as an insider
Perspective Therapeutics (CATX) Director Latest filing Nov 12, 2025
Track record
Did their buys beat the typical stock?
Open-market buys25
Quarters checked 6 months later3
Beat the typical stock 3 of 3
Quarters too new to check0
3 of 3 checked quarters beat the typical stock. A past record is data, not a forecast.
Perspective Therapeutics (CATX) Bought Nov 12, 2025 · $19.9K · 9,498 shares Beat typical Dec 31, 2025 $2.75 → Jun 30, 2026 $3.41 · +24.0% (typical stock +4.6%)
Perspective Therapeutics (CATX) Bought Mar 28–31, 2025 · $132K · 60,337 shares Beat typical Mar 31, 2025 $2.13 → Sep 30, 2025 $3.43 · +61.0% (typical stock +8.0%)
Perspective Therapeutics (CATX) Bought Nov 25, 2024 · $22.8K · 6,266 shares Beat typical Dec 31, 2024 $3.19 → Jun 30, 2025 $3.44 · +7.8% (typical stock −3.0%)
Perspective Therapeutics (CATX) Bought May 29–31, 2024 · $116K · 85,031 shares Not counted Not counted. We have no fund price for this stock on both Jun 30, 2024 and Dec 31, 2024.
Perspective Therapeutics (CATX) Bought Jan 24–30, 2024 · $195K · 315,081 shares Not counted Not counted. We have no fund price for this stock on both Mar 31, 2024 and Sep 30, 2024.
Perspective Therapeutics (CATX) Bought Dec 18–21, 2023 · $8.19K · 27,343 shares Not counted Not counted. We have no fund price for this stock on both Dec 31, 2023 and Jun 30, 2024.
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.